In Promise of True Liquid Biopsy for Cancer, Chip Company BioFluidica® Awarded $1.7 Million by National Cancer Institute/National Institutes of Health for Clinical Trial in Children with Acute Lymphoblastic Leukemia

PR Newswire, January 10, 2019 SAN DIEGO /PRNewswire/ -- BioFluidica, a privately held cancer diagnostics company, has been awarded an SBIR Phase II National Institutes of Health grant [Read More...]

In Promise of True Liquid Biopsy for Cancer, Chip Company BioFluidica® Awarded $1.7 Million by National Cancer Institute/National Institutes of Health for Clinical Trial in Children with Acute Lymphoblastic Leukemia2022-11-03T10:14:36-07:00

In Promise of True Liquid Biopsy for Cancer, BioFluidica® Launches Human Trial for Rapid Detection of Minimal Residual Disease in Acute Myeloid Leukemia from Peripheral Blood Using high through-put automation and programmable Microfluidic Chips

PR Newswire, May 19, 2018 SAN DIEGO /PRNewswire/ -- BioFluidica, a privately held cancer diagnostics company, today announced the continuation of a highly successful small patient study [Read More...]

In Promise of True Liquid Biopsy for Cancer, BioFluidica® Launches Human Trial for Rapid Detection of Minimal Residual Disease in Acute Myeloid Leukemia from Peripheral Blood Using high through-put automation and programmable Microfluidic Chips2022-11-03T10:16:40-07:00
Go to Top